Zeria PharmceuticalZERIA PHARMCEUTICAL CO., LTD.4559東証プライム医薬品FY ending Mar 2026, consolidated, J-GAAP
Revenue by business segment, and the profit each one keeps.
Geographic revenue reported in annual filings
No geographic revenue breakdown was disclosed.
※ Segment figures include inter-segment sales and do not sum to the company total
X-axis: segment revenue CAGR. Y-axis: latest operating margin. Bubble size: revenue.
Bubble size represents latest revenue. Segments without a CAGR are placed at the left edge; their horizontal position is not a growth value. Color indicates positive or negative margin.
| Segment | Revenue CAGR | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|---|
| Ethical drug business | +15.5%5y | 37,00618.7% | 43,14520.2% | 49,57218.7% | 58,97118.3% | 61,62619.8% |
| Consumer Health Care business | +3.9%5y | 22,37018.1% | 25,08619.8% | 25,99920.2% | 28,18022.7% | 27,38223.2% |
| Other | -0.8%5y | 157166.7% | 152159.1% | 155162.4% | 161151.7% | 151133.2% |
Top: revenue. Bottom: operating margin.
EDINET (FSA Japan)
有価証券報告書－第72期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
有価証券報告書－第71期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
有価証券報告書－第70期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
有価証券報告書－第69期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
有価証券報告書－第68期(令和3年4月1日－令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書－第67期(令和2年4月1日－令和3年3月31日)
Extracted from XBRL: 53 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.